Evidence map›Paper›PMID 40698232›Full record

ArticleCureus2025

The Identification and Challenges of Dopamine Dysregulation Syndrome: A Case Report.

Andrew Sulaiman, Idris Leppla

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Andrew SulaimanPsychiatry, Johns Hopkins University, Baltimore, USA.
Idris LepplaPsychiatry, Johns Hopkins University, Baltimore, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 48-year-old man with a history of opioid use disorder (unmanaged) and presumed Parkinson's disease presented to the emergency department secondary to worsening of his Parkinson's tremors/ambulatory dysfunction. He expressed that he was taking up to 20 doses of his carbidopa/levodopa (25mg-250mg pills for a total of >5g levodopa every day). The patient was admitted for the management of Parkinson's tremors and substance abuse. He was administered carbidopa/levodopa (25mg-250mg) every eight hours. Psychiatry was consulted due to marked functional fluctuations in his presentation and found that he demonstrated positive choreiform movements of the head/neck and upper extremity after taking the carbidopa. The patient's presentation prompted a suspicion of dopamine dysregulation syndrome (DDS). Supporting evidence included that the patient was insistent that the current regimen of carbidopa/levodopa wasn't managing symptoms, and even when the frequency was increased to every six hours, the patient expressed that his symptoms were still present and problematic. The patient stated that if the carbidopa/levodopa dosage wasn't further increased, he would leave the hospital. He ended up leaving against medical advice and was later ultimately re-admitted with the goal of transitioning to a rehabilitation facility for the treatment optimization of his substance use disorder and Parkinson's disease. This case demonstrates the challenges and presentation of DDS. DDS is a disorder marked by compulsive overuse of dopaminergic medication, which frequently occurs in individuals with Parkinson's disease. Additionally, this case reviews diagnostic criteria and moreover summarizes literature supporting methods of clinical management.

Indexed as

case presentationcl psychiatryddsdopamine dysregulation syndromeparkinson' s disease

Identifiers

PMID40698232
PMCPMC12282977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.